Paasa Logo
Solasia Pharma K.K. logo
4597JPXMarket closedOpens 9:00am JST

Solasia Pharma K.K.

¥31.00Last updated
+¥0.00 (0.00%)Past day
Timezone

Solasia Pharma K.K. (JPX: 4597) is trading at ¥31.00, about ₹19 at today's JPY/INR rate, as of 25 Sep 2026, 2:30 AM ET. Indian residents can buy Solasia Pharma K.K. from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:¥31.00
Previous close:¥31.00
Volume:48.22M

Today's low

¥30.00

Today's high

¥31.00

52 week low

¥21.00

52 week high

¥42.00

4597 opened at ¥31.00, closed previously at ¥31.00, and has traded between ¥21.00 and ¥42.00 over the past 52 weeks.

About

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.

Country
JP
CEO
Yoshihiro Arai
Exchange listed on
JPX
Industry
Drug Manufacturers - Specialty & Generic
Base currency
JPY
Full Time Employees
22
Sector
Healthcare
IPO date
27/03/2017

Key statistics

Avg. volume

70.43M

Market cap

¥8.46B

P/E Ratio

-9.31

Price-to-sales ratio

21.81

Enterprise value

¥7.25B

Free cash flow yield

-13.47%

Debt-to-equity ratio

0.05

Return on equity

-53.67%

ROIC

-57.55%

Beta

1.22

Dividend yield

0.00%

Last dividend

¥0.00

Financial overview

Revenue

¥429.00M

Earnings per share

-¥3.69

Free cash flow

-¥847.00M

Net profit margin

-231.96%

Gross margin

40.72%

EBITDA

-¥822.00M

Revenue growth

35.76%

Similar securities

This is not an investment recommendation

How to buy Solasia Pharma K.K. from India

Indian residents can buy Solasia Pharma K.K. shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to JPY.

  3. Search for Solasia Pharma K.K. and place an order

    Find Solasia Pharma K.K. by name or by its ticker, 4597, and choose an order type. The Tokyo Stock Exchange typically trades in units of 100 shares. Solasia Pharma K.K. trades 5:30 am – 12:00 pm IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Solasia Pharma K.K. position in JPY and INR. Solasia Pharma K.K. pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Solasia Pharma K.K. from India

Trading and taxes when buying Solasia Pharma K.K. from India

Trading and limits

Trading hours
9:00 am – 3:30 pm JST
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneSolasia Pharma K.K. does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Estate or inheritance tax
May applyJapan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.Estate tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Solasia Pharma K.K. stock?

Yes. Solasia Pharma K.K. (4597) has been listed on the Tokyo Stock Exchange since 2017, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to JPY. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Solasia Pharma K.K. share cost in rupees?

One Solasia Pharma K.K. share is ¥31.00 — about ₹19 at a JPY/INR rate of 0.6090 on 26 Sep 2026. Both the Solasia Pharma K.K. price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Solasia Pharma K.K. from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

What is the minimum I can buy of Solasia Pharma K.K.?

The Tokyo Stock Exchange typically trades in units of 100 shares.

How are gains on Solasia Pharma K.K. shares taxed in India?

Japan generally does not levy capital gains tax on non-resident individual investors, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the JPY/INR rate on the purchase and the sale date, so the rupee move counts alongside the Solasia Pharma K.K. price. Paasa issues a capital-gains statement for your return.

Does Solasia Pharma K.K. pay a dividend?

No. Solasia Pharma K.K. does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Solasia Pharma K.K. from India?

The Tokyo Stock Exchange trades 5:30 am – 12:00 pm IST in Indian time. It also halts for lunch, 8:00 am – 9:00 am IST. Orders can only execute during that window.

Is there estate or inheritance tax on Solasia Pharma K.K. shares held from India?

Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. It applies to your overall holdings in that jurisdiction rather than to any one position.

Do I have to declare Solasia Pharma K.K. shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Solasia Pharma K.K. holding, its cost and its closing value.

How do I sell Solasia Pharma K.K. and bring the money back to India?

You sell during market hours (5:30 am – 12:00 pm IST) and the proceeds settle in JPY in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.